Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues.

Hegde SS, Pulido-Rios MT, Luttmann MA, Foley JJ, Hunsberger GE, Steinfeld T, Lee T, Ji Y, Mammen MM, Jasper JR.

Pharmacol Res Perspect. 2018 Apr 30;6(3):e00400. doi: 10.1002/prp2.400. eCollection 2018 Jun.

2.

Transient receptor potential vanilloid 4 activation constricts the human bronchus via the release of cysteinyl leukotrienes.

McAlexander MA, Luttmann MA, Hunsberger GE, Undem BJ.

J Pharmacol Exp Ther. 2014 Apr;349(1):118-25. doi: 10.1124/jpet.113.210203. Epub 2014 Feb 6.

3.

Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases.

Salmon M, Luttmann MA, Foley JJ, Buckley PT, Schmidt DB, Burman M, Webb EF, DeHaas CJ, Kotzer CJ, Barrett VJ, Slack RJ, Sarau HM, Palovich MR, Lainé DI, Hay DW, Rumsey WL.

J Pharmacol Exp Ther. 2013 May;345(2):260-70. doi: 10.1124/jpet.112.202051. Epub 2013 Feb 22.

PMID:
23435542
4.

Design, synthesis and structure-activity relationship of N-substituted tropane muscarinic acetylcholine receptor antagonists.

Lainé DI, Yan H, Xie H, Davis RS, Dufour J, Widdowson KL, Palovich MR, Wan Z, Foley JJ, Schmidt DB, Hunsberger GE, Burman M, Bacon AM, Webb EF, Luttmann MA, Salmon M, Sarau HM, Umbrecht ST, Landis PS, Peck BJ, Busch-Petersen J.

Bioorg Med Chem Lett. 2012 May 1;22(9):3366-9. doi: 10.1016/j.bmcl.2012.02.015. Epub 2012 Feb 15.

PMID:
22460029
5.

Pharmacological characterization of GSK1004723, a novel, long-acting antagonist at histamine H(1) and H(3) receptors.

Slack RJ, Russell LJ, Hall DA, Luttmann MA, Ford AJ, Saunders KA, Hodgson ST, Connor HE, Browning C, Clark KL.

Br J Pharmacol. 2011 Nov;164(6):1627-41. doi: 10.1111/j.1476-5381.2011.01285.x.

6.

In vitro characterisation of the duration of action of the histamine-1 receptor antagonist azelastine.

Slack RJ, Hart AD, Luttmann MA, Clark KL, Begg M.

Eur J Pharmacol. 2011 Nov 30;670(2-3):586-92. doi: 10.1016/j.ejphar.2011.09.017. Epub 2011 Sep 21.

PMID:
21946109
7.

Design, synthesis, and structure-activity relationship of tropane muscarinic acetylcholine receptor antagonists.

Lainé DI, Wan Z, Yan H, Zhu C, Xie H, Fu W, Busch-Petersen J, Neipp C, Davis R, Widdowson KL, Blaney FE, Foley J, Bacon AM, Webb EF, Luttmann MA, Burman M, Sarau HM, Salmon M, Palovich MR, Belmonte K.

J Med Chem. 2009 Aug 27;52(16):5241-52. doi: 10.1021/jm900736e.

PMID:
19630384
8.

Discovery of novel 1-azoniabicyclo[2.2.2]octane muscarinic acetylcholine receptor antagonists.

Lainé DI, McCleland B, Thomas S, Neipp C, Underwood B, Dufour J, Widdowson KL, Palovich MR, Blaney FE, Foley JJ, Webb EF, Luttmann MA, Burman M, Belmonte K, Salmon M.

J Med Chem. 2009 Apr 23;52(8):2493-505. doi: 10.1021/jm801601v.

PMID:
19317446
9.

Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs.

Hay DW, Giardina GA, Griswold DE, Underwood DC, Kotzer CJ, Bush B, Potts W, Sandhu P, Lundberg D, Foley JJ, Schmidt DB, Martin LD, Kilian D, Legos JJ, Barone FC, Luttmann MA, Grugni M, Raveglia LF, Sarau HM.

J Pharmacol Exp Ther. 2002 Jan;300(1):314-23.

PMID:
11752131
10.

Stepwise modulation of neurokinin-3 and neurokinin-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists.

Blaney FE, Raveglia LF, Artico M, Cavagnera S, Dartois C, Farina C, Grugni M, Gagliardi S, Luttmann MA, Martinelli M, Nadler GM, Parini C, Petrillo P, Sarau HM, Scheideler MA, Hay DW, Giardina GA.

J Med Chem. 2001 May 24;44(11):1675-89.

PMID:
11356103
11.

Cysteinyl leukotriene receptor assays.

Muccitelli RM, Luttmann MA, Hay DW.

Curr Protoc Pharmacol. 2001 May;Chapter 4:Unit 4.16. doi: 10.1002/0471141755.ph0416s09.

PMID:
22293965
12.

Differential modulation of endothelin ligand-induced contraction in isolated tracheae from endothelin B (ET(B)) receptor knockout mice.

Hay DW, Douglas SA, Ao Z, Moesker RM, Self GJ, Rigby PJ, Luttmann MA, Goldie RG.

Br J Pharmacol. 2001 Apr;132(8):1905-15.

13.

Molecular and pharmacological characterization of the murine tachykinin NK(3) receptor.

Sarau HM, Feild JA, Ames RS, Foley JJ, Nuthulaganti P, Schmidt DB, Buckley PT, Elshourbagy NA, Brawner ME, Luttmann MA, Giardina GA, Hay DW.

Eur J Pharmacol. 2001 Feb 16;413(2-3):143-50.

PMID:
11226387
14.

Targeted disruption of the endothelin-B-receptor gene attenuates inflammatory nociception and cutaneous inflammation in mice.

Griswold DE, Douglas SA, Martin LD, Davis TG, Davis L, Ao Z, Luttmann MA, Pullen M, Nambi P, Hay DW, Ohlstein EH.

J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S78-81.

PMID:
11078342
15.

Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.

Sarau HM, Griswold DE, Bush B, Potts W, Sandhu P, Lundberg D, Foley JJ, Schmidt DB, Webb EF, Martin LD, Legos JJ, Whitmore RG, Barone FC, Medhurst AD, Luttmann MA, Giardina GA, Hay DW.

J Pharmacol Exp Ther. 2000 Oct;295(1):373-81.

PMID:
10992004
16.

Human urotensin-II is a potent spasmogen of primate airway smooth muscle.

Hay DW, Luttmann MA, Douglas SA.

Br J Pharmacol. 2000 Sep;131(1):10-2.

17.

Differences in time-related cardiopulmonary responses to hypoxia in three rat strains.

Bochnowicz S, Osborn RR, Luttmann MA, Louden C, Hart T, Hay DW, Underwood DC.

Clin Exp Hypertens. 2000 Jul;22(5):471-92.

PMID:
10937839
18.

Endothelin receptors and calcium translocation pathways in human airways.

Hay DW, Luttmann MA, Muccitelli RM, Goldie RG.

Naunyn Schmiedebergs Arch Pharmacol. 1999 May;359(5):404-10.

PMID:
10498291
19.

Endothelin B receptor modulates inflammatory pain and cutaneous inflammation.

Griswold DE, Douglas SA, Martin LD, Davis TG, Davis L, Ao Z, Luttmann MA, Pullen M, Nambi P, Hay DW, Ohlstein EH.

Mol Pharmacol. 1999 Oct;56(4):807-12.

PMID:
10496965
20.

Replacement of the quinoline system in 2-phenyl-4-quinolinecarboxamide NK-3 receptor antagonists.

Giardina GA, Artico M, Cavagnera S, Cerri A, Consolandi E, Gagliardi S, Graziani D, Grugni M, Hay DW, Luttmann MA, Mena R, Raveglia LF, Rigolio R, Sarau HM, Schmidt DB, Zanoni G, Farina C.

Farmaco. 1999 Jun 30;54(6):364-74.

PMID:
10443017
21.

Effect of SB 217242 on hypoxia-induced cardiopulmonary changes in the high altitude-sensitive rat.

Underwood DC, Bochnowicz S, Osborn RR, Luttmann MA, Louden CS, Hart TK, Elliott JD, Hay DW.

Pulm Pharmacol Ther. 1999;12(1):13-26.

PMID:
10208832
22.

Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig.

Underwood DC, Bochnowicz S, Osborn RR, Kotzer CJ, Luttmann MA, Hay DW, Gorycki PD, Christensen SB, Torphy TJ.

J Pharmacol Exp Ther. 1998 Dec;287(3):988-95.

PMID:
9864284
23.
24.

Functional and binding characterization of endothelin receptors in human bronchus: evidence for a novel endothelin B receptor subtype?

Hay DW, Luttmann MA, Pullen MA, Nambi P.

J Pharmacol Exp Ther. 1998 Feb;284(2):669-77.

PMID:
9454813
25.
27.

Nonpeptide endothelin receptor antagonists. VIII: attentuation of acute hypoxia-induced pulmonary hypertension in the dog.

Willette RN, Ohlstein EH, Mitchell MP, Sauermelch CF, Beck GR, Luttmann MA, Hay DW.

J Pharmacol Exp Ther. 1997 Feb;280(2):695-701.

PMID:
9023281
28.

Comparison of endothelin B (ETB) receptors in rabbit isolated pulmonary artery and bronchus.

Hay DW, Luttmann MA, Beck G, Ohlstein EH.

Br J Pharmacol. 1996 Jul;118(5):1209-17.

29.

Endothelin-1 receptor density, distribution, and function in human isolated asthmatic airways.

Goldie RG, Henry PJ, Knott PG, Self GJ, Luttmann MA, Hay DW.

Am J Respir Crit Care Med. 1995 Nov;152(5 Pt 1):1653-8.

PMID:
7582310
30.

Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs.

Underwood DC, Kotzer CJ, Bochnowicz S, Osborn RR, Luttmann MA, Hay DW, Torphy TJ.

J Pharmacol Exp Ther. 1994 Jul;270(1):250-9.

PMID:
8035322
31.

Differential antagonism of airway contractile responses to prostaglandin (PG)D2 and 9 alpha, 11 beta-PGF2 by atropine, SK&F 88046 and SQ 29,548 in the guinea pig.

Underwood DC, Muccitelli RM, Luttmann MA, Hay DW, Torphy TJ, Wasserman MA.

J Pharmacol Exp Ther. 1994 Jan;268(1):304-10.

PMID:
8301572
32.

Endothelin receptor subtypes in human and guinea-pig pulmonary tissues.

Hay DW, Luttmann MA, Hubbard WC, Undem BJ.

Br J Pharmacol. 1993 Nov;110(3):1175-83.

33.

Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle.

Torphy TJ, Undem BJ, Cieslinski LB, Luttmann MA, Reeves ML, Hay DW.

J Pharmacol Exp Ther. 1993 Jun;265(3):1213-23.

PMID:
8389856

Supplemental Content

Loading ...
Support Center